Passage Bio
PASG
66 hedge funds and large institutions have $863M invested in Passage Bio in 2020 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 11 closing their positions.
191% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 11
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
87% more capital invested
Capital invested by funds: $462M → $863M (+$401M)
47% more funds holding
Funds holding: 45 → 66 (+21)
0.15% more ownership
Funds ownership: 3.34% → 3.48% (+0.15%)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$36.7M |
| 2 |
BlackRock
New York
|
+$17.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.6M |
| 4 |
HCM
Highline Capital Management
New York
|
+$6.26M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.75M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$10.6M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$7.94M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.82M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.01M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.65M |
PASG Hedge Fund Activity: Q2 2020 in Review
66 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q2 2020, worth a combined $863M — up 87% from $462M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new PASG positions and 11 closed out — a net gain of 21 holders — while 10 added to existing stakes and 13 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $36.7M. The largest seller was Deerfield Management, exiting entirely with an estimated $10.6M sold.
- 66 institutional investors held Passage Bio (PASG) as of Q2 2020, up from 45 in Q1 2020.
- Funds reported $863M of Passage Bio stock for Q2 2020, up 87% quarter-over-quarter.
- 32 funds opened new Passage Bio positions in Q2 2020 and 11 closed out, a net change of +21 holders.
- The largest Passage Bio buyer in Q2 2020 was Fidelity Investments, an estimated $36.7M added.
- The largest Passage Bio seller in Q2 2020 was Deerfield Management, an estimated $10.6M sold.
Based on aggregated 13F filings for Q2 2020.